Overview A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects Status: Recruiting Trial end date: 2021-02-01 Target enrollment: Participant gender: Summary This is a randomized, single-blind, placebo-controlled, once daily (QD) dose study of CRV431 in presumed NASH F2/F3 subjects. Phase: Phase 2 Details Lead Sponsor: Hepion Pharmaceuticals, Inc.